DTIL, US74019P2074

Precision BioSciences outlines two clinical programs and 5 analysts cover DTIL stock

Published on 10/05/2026 at 04:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Precision held USD 112.0 million in cash at the end of Q2 2026, with runway through 2028. DTIL stock has 5 ratings and a USD 32.25 target.

DTIL, US74019P2074, Illustration mit AI erstellt.

Precision BioSciences (US74019P2074) outlined two clinical gene-editing programs on September 16, 2026, while 5 analysts covered DTIL stock, according to Investing.com and MarketBeat. The company is advancing PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy.

Two programs move through trials

Investing.com reported that PBGENE-HBV is being tested in the Phase I ELIMINATE-B trial, while PBGENE-DMD is in the Phase I/II FUNCTION-DMD trial. The transcript said PBGENE-DMD began dosing in August 2026 at Arkansas Children's Hospital, with a second site activated at Washington University in St. Louis.

The hepatitis B program had dosed 16 patients across 38 administrations, according to the same September 16, 2026 conference transcript. Clinical data released in May 2026 showed a one-log reduction in cccDNA-derived transcripts after two doses, while all patients with detectable baseline pgRNA reached durable undetectable levels.

Cash runway meets clinical risk

Precision said it held USD 112.0 million in cash and cash equivalents at the end of the second quarter of 2026 and expected that balance to fund operations through 2028, Investing.com reported. That runway gives the company time to produce the next clinical milestones, but the same transcript described both lead programs as early-stage studies requiring additional patient data.

MarketBeat reported that Precision's second-quarter 2026 earnings per share loss was USD 1.26, compared with a consensus loss of USD 0.80. The USD 0.46 shortfall puts the cash runway in sharper context: clinical progress remains the central valuation driver while operating results remain negative.

Analyst target stays far above price

MarketBeat listed a Moderate Buy consensus, 5 analysts and a USD 32.25 average price target as of October 4, 2026. The target is a third-party market view rather than company guidance, and its distance from the last available US quote highlights the uncertainty around early clinical data.

Last Lang and Schwarz reference

The last prior close at Lang & Schwarz was EUR 5.61 on October 2, 2026. Precision BioSciences is listed on Nasdaq under DTIL, and its business centers on the ARCUS genome-editing platform, according to the company's investor-relations profile.